RE: Blautix - As a stand Alone Deal12 Apr 2022 16:08
Extract Copy of Transcript from Blautix Webinar in Oct 2021
Just a reminder of DP & Glen Durado's comments on analysts quesions :-
"Edward Thomason, N+1 Singer
Yeah, follow that. And look two more if I may. I just want to understand the intention after this. Whether you talk about plans for Phase II,
would that be again across all subtypes or just for IBS-M or and again, just the corporate strategy for Blautix now and whether you will look
to do develop this independently or with a partner.
Duncan Peyton, Chief Executive Officer, 4D pharma
That’s a good question, Edward. I think you know we’re still going through the analysis as is, working out what the trial would look like, so it’s
still early days in terms of exactly which path we’re going to take. I think, as you know, and I’ll let Glenn come on this, we’ve been talking to
a few potential partners as well, so we'll follow all those conversations as well, Glenn?
Glenn Dourado, Chief Business Officer, 4D pharma
Yeah, thanks Duncan. Just to add on tha, we have been in constant contact with all the major players in the IBS space as well as other
companies that have expressed interest given the stage that the program is at, and so a number of them were waiting for these Phase II
results to be released so we'll certainly follow up with them and see where the interest lies but there is definite interest from major players."